Amneal Pharmaceuticals Inc (AMRX) - News Archive

Amneal Pharmaceuticals Expands to Meet Rising Demand in U.S. Pharmaceutical Manufacturing In a strategic move to bolster its capabilities in advanced pharmaceutical manufacturing, Amneal Pharmaceuticals Inc. (NASDAQ: AM...

Amneal Pharmaceuticals Strategic Moves in the Biopharmaceutical Arena: A Focus on Innovation and Collaboration Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a reputed name in the global pharmaceutical industry, has embar...

Approval of BORUZU: A Game-Changer in Bortezomib Administration Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited have jointly announced the U.S. Food and Drug Administration (FDA) approval of BORUZU, marking a s...

Amneal and Shilpa Secure U.S. FDA Approval for BORUZU: A Ready-to-Use Bortezomib Injection for Subcutaneous Administration Bridgewater, N.J. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (Amneal) and Shilpa Medicare Limit...

BRIDGEWATER, N.J. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has achieved a significant milestone that promises to enhance clinical practices in the administration of anesthesia. The U.S. Food and Drug Administration (...

In a significant advancement for Parkinson’s disease (PD) management, Amneal Pharmaceuticals, Inc. has received U.S. Food and Drug Administration (FDA) approval for CREXONT, an innovative formulation of carbidopa and le...

Recent Advances in Parkinson s Disease Treatment and Injectable Medications: A Spotlight on Amneal Pharmaceuticals Amneal Pharmaceuticals has garnered attention recently for its notable developments in the pharmaceutica...

The pharmaceutical landscape is continuously evolving, with companies striving to enhance drug delivery systems and patient outcomes. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey...

In a significant advancement for the pharmaceutical industry and healthcare providers, Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), based in Bridgewater, New Jersey, has announced the receipt of New Drug Application (ND...

Amneal Pharmaceuticals, a prominent player in the pharmaceutical industry, has recently made significant advancements in their portfolio with the launch of FOCINVEZ, a ready-to-use injectable, and the addition of six ne...

Amneal Pharmaceuticals Ramps Up Biosimilars and Injectables Portfolios to Address Critical ShortagesBridgewater, N.J. - In a strategic move to address critical shortages and cater to the growing demand for quality healt...

Amneal Pharmaceuticals Releases 2023 Environmental, Social, and Governance Report: A Commitment to Sustainable Business Practices and Social ResponsibilityAmneal Pharmaceuticals, a leading global pharmaceutical company,...

Amneal Pharmaceuticals Bolsters Injectables Portfolio with Six New Therapies, Surpassing 40 Products for U.S. MarketAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has recently demonstrated impressive growth with the additi...

Amneal Pharmaceuticals, Inc. has recently entered into an exclusive licensing agreement with Zambon Biotech SA to bring a novel treatment for Parkinson s disease (PD) to the European Union, United Kingdom, and Switzerla...

Amneal Pharma Resubmits New Drug Application for IPX203 to FDA and Announces Move to Nasdaq; Partners with BIAL for U.S. Licensing Agreement on ONGENTYSAmneal Pharmaceuticals, Inc. (Amneal), a leading global pharmaceuti...

In an exciting development for pharmaceutical science, Amneal Pharmaceuticals Inc. recently announced two significant moves that could potentially reshape specific areas in healthcare and treatment. Firstly, the company...

Amneal Pharmaceuticals Makes Historic Move to Nasdaq, Driving Growth and Innovation in Biotech IndustryBridgewater, New Jersey - In a groundbreaking decision, Amneal Pharmaceuticals, Inc. (Amneal) (NYSE: AMRX) announced...

Amneal Pharmaceuticals Secures U.S. Licensing Agreement with BIAL for ONGENTYS (opicapone)Bridgewater, N.J. & Porto, Portugal- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and BIAL - Portela & Ca., S.A. (BIAL) have recentl...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has recently made an exciting addition to its portfolio by acquiring the rights to Icosapent ethyl acid soft gel capsules. This innovative product, which references VASCEPA, has...